|
Jul 29
|
Liquidia's Yutrepia Drug Launch Expectations 'Overly Optimistic,' Oppenheimer Says
|
|
Jul 24
|
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
|
|
Jul 18
|
3 Growth Companies With Insider Ownership Up To 25%
|
|
Jul 15
|
Liquidia Stock Gets Relative Strength Rating Lift
|
|
Jul 15
|
Liquidia Receives $50M from HCRx, Accelerates YUTREPIA’s Commercial Launch Following Favorable Court Ruling
|
|
Jul 10
|
Liquidia's (NASDAQ:LQDA) growing losses don't faze investors as the stock rallies 12% this past week
|
|
Jun 23
|
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
|
|
Jun 19
|
Top Growth Companies With Insider Stakes In June 2025
|
|
Jun 10
|
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
|
|
Jun 2
|
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
|
|
May 28
|
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
|
|
May 24
|
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute
|
|
May 23
|
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
|
|
Mar 14
|
One Liquidia Insider Raised Their Stake In The Previous Year
|
|
Mar 12
|
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
|
|
Feb 24
|
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
|
|
Feb 21
|
US Growth Stocks With High Insider Ownership Seeing Up To 48% Revenue Growth
|
|
Oct 9
|
Liquidia Corp (LQDA) Q2 2024 Earnings Call Highlights: Navigating Challenges and Opportunities ...
|
|
Oct 8
|
Liquidia Technologies (LQDA) Surges 11.2%: Is This an Indication of Further Gains?
|
|
Oct 7
|
Liquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute
|